Answers are grounded in this paper and cite their sources.
Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii . We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant A. baumannii infections.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: